# An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)

> **NCT07217860** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Xenon Pharmaceuticals Inc.** · enrollment: 400 (estimated)

## Conditions studied

- Bipolar Depression
- Bipolar I Disorder
- Bipolar Disorder
- Bipolar II Disorder

## Interventions

- **DRUG:** Azetukalner

## Key facts

- **NCT ID:** NCT07217860
- **Lead sponsor:** Xenon Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-10-30
- **Primary completion:** 2029-06
- **Final completion:** 2029-08
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07217860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07217860, "An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07217860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*